MEDIA RELEASE 7 September 2022 New Zealanders living with multiple myeloma, a deadly, relapsing/remitting blood cancer, are mounting a major,...
Blood cancer
Rachel Smalley: 1,000 kiwis will die while Pharmac takes eight months to make a decision
OPINION: How long does it take you to make a decision about whether or not to buy something? You’ve got all the information in front of you. You...
Multiple Myeloma Queenstown Summit
In August 2022, Myeloma New Zealand is hosting its 4th Myeloma Summit for medical professionals in Queenstown. Held in 2016,2018, 2020 and now again...
Multiple Myeloma CEO, Dr Ken Romeril, on The AM Show this morning, calling for a release of the independent report on Pharmac
Please click on this link to watch the interview: https://fb.watch/cWyMuvV_QO/
DOCTOR CALLS ON MINISTER LITTLE TO RELEASE ‘BURIED’ INDEPENDENT REPORT ON PHARMAC
MEDIA RELEASE DOCTOR CALLS ON MINISTER LITTLE TO RELEASE ‘BURIED’ INDEPENDENT REPORT ON PHARMAC The final report of the Independent Pharmac Review...
Multiple Myeloma Media Release
The Cancer Control Agency’s analysis of the gap between Australia and New Zealand in funding 18 selected medicines with substantial clinical benefit...
COVID-19 information for patients and whānau with cancer.
This link here: Te Aho o Te Kahu - Cancer during COVID-19 contains information for patients and whānau with cancer. Cancer treatment continues at...
Pharmac Review Final Report – Update
In a radio interview today, Health Minister Andrew Little said the final Pharmac Review report will be publicised "in a matter of a few...
Endorsers of the ICBCC Patient Impact Statement
Last Thursday 24 February the ICBCC Policy Strategy Working Group met to discuss on the Policy Strategy to address the specific impact of the...
Myeloma Australia’s Medical and Scientific Advisory Group (MSAG), article of the week
The primary analysis of the ICARIA-MM study showed significant improvement in progression-free survival with addition of isatuximab to...
CD38 directed therapy shows promise in Multiple Myeloma
Isatuximab continues to show promise as a standard of care therapy for patients with multiple myeloma refractory to lenalidomide and proteasome...
Australians have limited awareness of blood cancers, – new survey
Australians will not seek help for blood cancer symptoms: survey (thelimbic.com)